Incyte (INCY) Tax Provisions (2010 - 2026)
Incyte (INCY) reported Tax Provisions of $40.3 million for Q1 2026, down 47.0% on a YoY basis from $76.0 million in Q1 2025, and down 55.58% quarter-over-quarter from $90.7 million in Q4 2025.
Incyte (INCY) Tax Provisions (2010 - 2026) Analysis & Trends
Incyte has reported Tax Provisions for 16 years, with the latest figure at $40.3 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions fell 47.0% year-over-year to $40.3 million; the trailing twelve-month figure through Mar 2026 stood at $342.1 million (up 16.6% YoY), and the FY2025 full-year result was $377.8 million, up 33.02% from the prior year.
- Tax Provisions for Q1 2026 stood at $40.3 million, down from $90.7 million in the prior quarter.
- The five-year high for Tax Provisions was $153.0 million in Q2 2025, with the low at $30.2 million in Q1 2023.
- Historically, Tax Provisions has averaged $66.3 million across 5 years, with a median of $62.5 million in 2023.
- Annual changes were most pronounced in 2022 — Tax Provisions jumped 206.38% — and 2026, when it tumbled 47.0%.
- Incyte's Tax Provisions stood at $52.2 million in 2022, then surged by 33.98% to $69.9 million in 2023, then soared by 61.01% to $112.5 million in 2024, then retreated by 19.42% to $90.7 million in 2025, then tumbled by 55.58% to $40.3 million in 2026.
- The last three Tax Provisions figures came in at $40.3 million (Q1 2026), $90.7 million (Q4 2025), and $58.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 216,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 40.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.27 Mn |
| Dec 31, 2025 | 90.66 Mn |
| Sep 30, 2025 | 58.14 Mn |
| Jun 30, 2025 | 153.01 Mn |
| Mar 31, 2025 | 75.99 Mn |
| Dec 31, 2024 | 112.51 Mn |
| Sep 30, 2024 | 50.07 Mn |
| Jun 30, 2024 | 54.82 Mn |
| Mar 31, 2024 | 66.61 Mn |
| Dec 31, 2023 | 69.88 Mn |
| Sep 30, 2023 | 62.53 Mn |
| Jun 30, 2023 | 74.06 Mn |
| Mar 31, 2023 | 30.15 Mn |
| Dec 31, 2022 | 52.15 Mn |
| Sep 30, 2022 | 35.81 Mn |
| Jun 30, 2022 | 67.95 Mn |
| Mar 31, 2022 | 32.54 Mn |
| Dec 31, 2021 | -443.83 Mn |
| Sep 30, 2021 | 27.70 Mn |
| Jun 30, 2021 | 22.18 Mn |